» Articles » PMID: 37822878

Protective Effect of Heat-processed on High Fat Diet-induced Glucose Metabolic Disorders Mice

Overview
Journal Front Pharmacol
Date 2023 Oct 12
PMID 37822878
Authors
Affiliations
Soon will be listed here.
Abstract

Glucose metabolic disorders (GMD) can promote insulin resistance (IR) and diabetes, and damage liver and kidney. is commonly used in the clinical treatment of diabetes, but the research on its main active constituents and GMD has not been reported yet. This study explores the therapeutic potential of gypenosides of heat-processed (HGyp) on high-fat diet-induced GMD in mice. HGyp was administered at different doses for 12 weeks. The investigation encompassed an array of parameters, including body weight, blood lipids, blood glucose, and liver tissue components. Metabolomic and network analyses were conducted to uncover potential targets and pathways associated with HGyp treatment. The results revealed that HGyp alleviated GMD by reducing body weight, blood glucose, and improving blood lipids levels, while increasing liver glycogen and antioxidant enzyme levels. Additionally, HGyp exhibited protective effects on liver and kidney health by reducing tissue damage. Fourteen blood components were detected by LC-MS. Metabolomic and network analyses indicated the potential engagement of the AGE-RAGE signaling pathway in the therapeutic effects of HGyp.Furthermore, Western blot and ELISA assays confirmed that HGyp upregulated GLO1 and GLUT4 while down-regulating AGEs and RAGE expression in liver tissue. In light of these findings, HGyp demonstrates promise as a potential therapeutic candidate for combating GMD, warranting further exploration in the development of therapeutic strategies or functional products.

Citing Articles

Utilizing High-Resolution Mass Spectrometry Data Mining Strategy in R Programming Language for Rapid Annotation of Absorbed Prototypes and Metabolites of Gypenosides.

Li X, Zhang Q, Li Y, Qin L, Wu D, Tan D Molecules. 2025; 30(4).

PMID: 40005091 PMC: 11858763. DOI: 10.3390/molecules30040779.


The potential of in the treatment of hyperlipidemia and its interaction with the LOX1-PI3K-AKT-eNOS pathway.

Shen Z, Gao X, Huang D, Xu X, Shen J Food Sci Nutr. 2024; 12(10):8000-8012.

PMID: 39479713 PMC: 11521742. DOI: 10.1002/fsn3.4250.


Gypenoside inhibits gastric cancer proliferation by suppressing glycolysis via the Hippo pathway.

Pan L, Lan B, Li S, Jin Y, Cui M, Xia Y Sci Rep. 2024; 14(1):19003.

PMID: 39152152 PMC: 11329763. DOI: 10.1038/s41598-024-69435-y.


Label-free proteomic analysis reveals the hepatoprotective mechanism of gypenosides in liver injury rats.

Chen Y, Ma L, Wang Y, Zhang J, Pei T, Wang M Front Pharmacol. 2024; 15:1417575.

PMID: 38994199 PMC: 11236725. DOI: 10.3389/fphar.2024.1417575.

References
1.
Lascar N, Brown J, Pattison H, Barnett A, Bailey C, Bellary S . Type 2 diabetes in adolescents and young adults. Lancet Diabetes Endocrinol. 2017; 6(1):69-80. DOI: 10.1016/S2213-8587(17)30186-9. View

2.
Liu H, Li X, Duan Y, Xie J, Piao X . Mechanism of gypenosides of Gynostemma pentaphyllum inducing apoptosis of renal cell carcinoma by PI3K/AKT/mTOR pathway. J Ethnopharmacol. 2021; 271:113907. DOI: 10.1016/j.jep.2021.113907. View

3.
Drucker D . Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018; 27(4):740-756. DOI: 10.1016/j.cmet.2018.03.001. View

4.
Salpeter S, Greyber E, Pasternak G, Salpeter E . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; (4):CD002967. PMC: 7138050. DOI: 10.1002/14651858.CD002967.pub4. View

5.
Xu F, Zhu Y, Lu M, Qin L, Zhao D, Ren T . Effects of Hydroxy-Alpha-Sanshool on Intestinal Metabolism in Insulin-Resistant Mice. Foods. 2022; 11(14). PMC: 9322383. DOI: 10.3390/foods11142040. View